Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437452 | 0.88 | TAS1R3 (0.52) | TAS1R3TAS1R1CA2CA1SMN1; SMN2 | |
| SCHEMBL5204535 | 0.83 | CA12 (0.46) | TAS1R3TAS1R1CA2CA1MAPK1 | |
| SCHEMBL9819625 | 0.83 | ZDHHC20 (0.46) | TAS1R3TAS1R1CA2CA1PLA2G2C | |
| SCHEMBL5208140 | 0.83 | TAS1R3 (0.40) | TAS1R3TAS1R1CA2CA1PLA2G2C | |
| SCHEMBL5208917 | 0.81 | TAS1R3 (0.46) | TAS1R3TAS1R1CA2CA1PLA2G2C | |
| SCHEMBL8436642 | 0.78 | TAS1R3 (0.46) | TAS1R3TAS1R1CA2CA1MAPK1 | |
| SCHEMBL7211081 | 0.78 | ZDHHC20 (0.49) | TAS1R3TAS1R1CA1PLA2G2CMAPK1 | |
| SCHEMBL1388451 | 0.78 | CA2 (0.44) | CA2CA1PLA2G2CMAPK1CTSK | |
| SCHEMBL13715798 | 0.78 | PLA2G2C (0.59) | CA2CA1PLA2G2CMAPK1 | |
| SCHEMBL1388452 | 0.78 | CA2 (0.48) | TAS1R3TAS1R1CA2CA1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958292-B1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-10 | — | — | US | disclosed |
| US-6165944-A | 4-(3-heterocyclyl-1-benzoyl) pyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| EP-0777658-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | TAS1R3 1425/4885TAS1R1 1133/4885CA2 389/4885 |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | TAS1R3 1737/4885TAS1R1 1487/4885CA2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.